Login to Your Account



OSI, Genentech Submit NDA For Tarceva As Therapy For NSCLC

By Kim Coghill


Tuesday, August 3, 2004
OSI Pharmaceuticals Inc. and partner Genentech Inc. completed the submission of a new drug application for Tarceva, a drug for the treatment of patients with advanced non-small-cell lung cancer who have failed chemotherapy. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription